Efficacy and Safety of Empagliflozin in NODAT

Launched by RENJI HOSPITAL · Aug 20, 2018

Keywords

ClinConnect Summary

In recent years, with the development of transplantation technology and immunosuppressive agents, kidney transplantation has made considerable progress. However, for metabolic disorders after kidney transplantation, such as new diabetes after kidney transplantation, there is still insufficient awareness. Since 1964, Starlz et al. first discovered and proposed New-onset diabetes after kidney transplantation（NODAT） in patients after renal transplantation. Scholars from all countries have paid considerable attention to it. The Chinese guidelines indicate that NODAT can increase the risk of gra...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Single kidney transplantation
• • Normal glucose tolerance or Pre-Diabetes mellitus before transplantation
• • According to Oral glucose tolerance test results to make the diagnosis of NODAT
• • Standard triple immunosuppression therapy
• • HbA1c≤10%
• • Steady hormone usage
• • BMI 18.5-30kg/m2
• • Patient informed consent
• Exclusion Criteria:
• • Diabetes patients before transplantation
• • Pregnancy pregnancy
• • Type 1 diabetes after kidney transplantation
• • Severe liver function impairment (AST/ALT 3 times standard value)
• • Severely impaired renal function (eGFR\<45)
• • Having uncontrolled diseases
• • History of cancer in the past 5 years (except basal cell carcinoma) and/or cancer treatment
• • Participating in another trial involving the study drug with in 30 days
• • Premenopausal women (1 year before the last menstrual period ≤ informed consent)
• • Alcohol or drug abuse within 3 months of informed consent, affecting compliance Need other drugs to control NODAT